ROOSE is filed with the CBE under the catch-all “Niet-gespecialiseerde groothandel”, a code that says little about what the company actually does. Private Limited, started on 13 February 1997, 1 establishment.

What is the address of ROOSE?

The registered office of ROOSE is located at Gistelsesteenweg 160, 8460 Oudenburg.

Is ROOSE still active?

Yes. According to the CBE (29 October 2026) ROOSE is active, legal situation “Normale toestand”, started on 13 February 1997.

Is ROOSE registered on Peppol?

Yes, ROOSE is registered on the Peppol network with ID 0208:0459875218.

What is the enterprise number of ROOSE?

The enterprise number of ROOSE is BE0459875218.

When was ROOSE founded?

ROOSE was founded on 13 February 1997.

Who are the directors of ROOSE?

According to the 2025 annual accounts, the directors of ROOSE are: Carivaro BV, KAFINCO BV, Shatal BV.

Is ROOSE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 February 1997; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did ROOSE make in 2025?

ROOSE recorded a loss after taxes of € 447,083 in financial year 2025.

What is the revenue of ROOSE?

In its most recent annual accounts (2025), ROOSE reported revenue of € 7,363,743.

ROOSE (Private Limited) - Oudenburg - BE0459875218

Dossier ROOSE, printed on 29 October 2026 from databakkes.be/en/0459875218/roose. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ROOSE from Oudenburg, company number BE0459875218, closed financial year 2025 with a result of € -447,083 after tax. For that financial year ROOSE recorded revenue of € 7.4 million and equity of € 641,437. Compared with financial year 2024, the result moved from € 590,841 to € -447,083. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.

What it is worth Healthy

€ 641,437

▼ 46% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -447,083

▼ still € 590,841 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 211,718

▼ 22% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 622,845.

People and assets in 2025

Vehicles and equipment

€ 112,467

▼ 32% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 1.2 million

▼ 5% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 979,747

▲ 17% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 61,672

▲ 6% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	-	-	€ 7,389,171 Revenue 2024: € 7,389,171 First fiscal year in the series	€ 7,363,743 Revenue 2025: € 7,363,743 Unchanged (€ 7,389,171) Unfavourable step
Gross margin	€ 449,131 Gross margin 2022: € 449,131 First fiscal year in the series	€ 606,670 Gross margin 2023: € 606,670 ▲ 35% vs 2022 (€ 449,131) Favourable step	€ 820,257 Gross margin 2024: € 820,257 ▲ 35% vs 2023 (€ 606,670) Favourable step	€ -282,914 Gross margin 2025: € -282,914 ▼ € 1.1 million vs 2024 (€ 820,257) Unfavourable step	▼ € 1.1 million
Profit after taxes	€ 261,443 Profit after taxes 2022: € 261,443 First fiscal year in the series	€ 551,515 Profit after taxes 2023: € 551,515 ▲ 111% vs 2022 (€ 261,443) Favourable step	€ 590,841 Profit after taxes 2024: € 590,841 ▲ 7% vs 2023 (€ 551,515) Favourable step	€ -447,083 Profit after taxes 2025: € -447,083 ▼ € 1 million vs 2024 (€ 590,841) Unfavourable step	▼ € 1 million
Equity	€ 1,199,913 Equity 2022: € 1,199,913 First fiscal year in the series	€ 1,351,428 Equity 2023: € 1,351,428 ▲ 13% vs 2022 (€ 1,199,913) Favourable step	€ 1,188,520 Equity 2024: € 1,188,520 ▼ 12% vs 2023 (€ 1,351,428) Unfavourable step	€ 641,437 Equity 2025: € 641,437 ▼ 46% vs 2024 (€ 1,188,520) Unfavourable step	▼ 46%
Total debts	€ 1,205,081 Total debts 2022: € 1,205,081 First fiscal year in the series	€ 1,206,607 Total debts 2023: € 1,206,607 Unchanged (€ 1,205,081) Unfavourable step	€ 2,132,700 Total debts 2024: € 2,132,700 ▲ 77% vs 2023 (€ 1,206,607) Unfavourable step	€ 2,445,747 Total debts 2025: € 2,445,747 ▲ 15% vs 2024 (€ 2,132,700) Unfavourable step	▲ 15%
Cash	€ 572,484 Cash 2022: € 572,484 First fiscal year in the series	€ 623,464 Cash 2023: € 623,464 ▲ 9% vs 2022 (€ 572,484) Favourable step	€ 271,512 Cash 2024: € 271,512 ▼ 56% vs 2023 (€ 623,464) Unfavourable step	€ 211,718 Cash 2025: € 211,718 ▼ 22% vs 2024 (€ 271,512) Unfavourable step	▼ 22%
Land & buildings	€ 20,806 Land & buildings 2022: € 20,806 First fiscal year in the series	€ 17,338 Land & buildings 2023: € 17,338 ▼ 17% vs 2022 (€ 20,806) Unchanged	€ 13,871 Land & buildings 2024: € 13,871 ▼ 20% vs 2023 (€ 17,338) Unchanged	€ 10,403 Land & buildings 2025: € 10,403 ▼ 25% vs 2024 (€ 13,871) Unchanged	▼ 25%
Retained profit	€ 1,181,321 Retained profit 2022: € 1,181,321 First fiscal year in the series	€ 1,332,836 Retained profit 2023: € 1,332,836 ▲ 13% vs 2022 (€ 1,181,321) Favourable step	€ 1,169,928 Retained profit 2024: € 1,169,928 ▼ 12% vs 2023 (€ 1,332,836) Unfavourable step	€ 622,845 Retained profit 2025: € 622,845 ▼ 47% vs 2024 (€ 1,169,928) Unfavourable step	▼ 47%
Dividend	€ 200,000 Dividend 2022: € 200,000 First fiscal year in the series	€ 400,000 Dividend 2023: € 400,000 ▲ 100% vs 2022 (€ 200,000) Unchanged	€ 753,750 Dividend 2024: € 753,750 ▲ 88% vs 2023 (€ 400,000) Unchanged	€ 100,000 Dividend 2025: € 100,000 ▼ 87% vs 2024 (€ 753,750) Unchanged	▼ 87%
Bank debt	€ 165,000 Bank debt 2022: € 165,000 First fiscal year in the series	€ 111,776 Bank debt 2023: € 111,776 ▼ 32% vs 2022 (€ 165,000) Favourable step	€ 1,230,000 Bank debt 2024: € 1,230,000 ▲ € 1.1 million vs 2023 (€ 111,776) Unfavourable step	€ 1,170,819 Bank debt 2025: € 1,170,819 ▼ 5% vs 2024 (€ 1,230,000) Favourable step	▼ 5%
Balance sheet total	€ 2,404,994 Balance sheet total 2022: € 2,404,994 First fiscal year in the series	€ 2,558,035 Balance sheet total 2023: € 2,558,035 ▲ 6% vs 2022 (€ 2,404,994) Unchanged	€ 3,321,219 Balance sheet total 2024: € 3,321,219 ▲ 30% vs 2023 (€ 2,558,035) Unchanged	€ 3,087,184 Balance sheet total 2025: € 3,087,184 ▼ 7% vs 2024 (€ 3,321,219) Unchanged	▼ 7%

Key figures of ROOSE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ROOSE?

What happened at ROOSE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 1, 2026 New annual accounts for financial year 2025: loss of € 447,083 (▼ € 1 million vs 2024). Source: NBB ↗
2025 KAFINCO BV became a director. NBB
2025 Shatal BV stepped down as director. NBB
2024 Carivaro BV became a director. NBB
2024 Shatal BV became a director. NBB
Feb 25, 1997 New establishment in Oudenburg. KBO
Feb 13, 1997 Start of the company according to the CBE. KBO

In short

From € 261,443 profit in 2022 to € 447,083 loss in 2025.

Paid € 276,670 in corporate taxes since 2022.

Best year ever: 2024, with € 590,841 profit.

Paid out € 1.5 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

ECG Nutrition and Supplements 100%

CARIVARO 99.7%

The stake of ECG Nutrition and Supplements, CARIVARO comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

ROOSE

Westpaille 100%

Behind ROOSE are Carivaro BV and KAFINCO BV. The shares are held by ECG Nutrition and Supplements (100%) and CARIVARO (99.7%). It owns 100% of Westpaille itself.

Directors

According to the 2025 annual accounts

Carivaro BV

Director · represented by Carla Vanhessche

Also active at: WESTPAILLE

since 2024

KAFINCO BV

Director · represented by Julie Santens

Also active at: DESOTEC, D.E.S.O.T.E.C. INTERNATIONAL, Zoolyx, EQUINE CARE GROUP, David Bidco, ECG Labs, ECG Medical Care, ECG Nutrition and Supplements +1 more

since 2025

Shatal BV

Director · represented by Tom Mariën

Also active at: Dierenartsenpraktijk Hendrikx - Deuss, WESTPAILLE, ECG Clinics, Zoolyx, EQUINE CARE GROUP, EQUITOM LIEGE, REVERDY BENELUX, ECG Labs +4 more

since 2024 · until 2025

Shareholders

ECG Nutrition and Supplements

100%

CARIVARO

99.7%

Participations

Westpaille

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Gistelsesteenweg 160

8460 Oudenburg

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

WESTPAILLE same network

€ 1.8 million revenue · 2025

CARIVARO same network

€ 710,570 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0459.875.218

VAT number

BE 0459.875.218

Registered office

Gistelsesteenweg 160, 8460 Oudenburg

Names & denominations

ROOSE

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

13 February 1997

Peppol

Active · Active since 23 Jan 2026

Activities · NACE

Niet-gespecialiseerde groothandel

Overige groothandel

View on CBE Public ↗ Annual accounts (NBB) ↗

ROOSE

Financials

What happened to ROOSE?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions